BioCentury | Oct 6, 2014
Finance

Kadmon maneuvers

...and Co. (NYSE:LLY) for $6.8 billion in 2008. Kadmon has four drug discovery platforms: metabolomics; chiromics...
BioCentury | Nov 12, 2012
Company News

Chiromics, Bristol-Myers, GlaxoSmithKline deal

...pharmas to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics'...
...Bristol-Myers. Bristol-Myers and Chiromics did not disclose additional details, while GlaxoSmithKline could not be reached. Chiromics'...
...Chiromics was founded in 2009 by David MacMillan, a professor of chemistry at Princeton University. Chiromics LLC...
BioCentury | Nov 10, 2012
Company News

Chiromics in pair of pharma discovery deals

...NYSE:GSK) to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics'...
...and an exclusive license to a proprietary compound collection. Using its Chalis hit recognition algorithm, Chiromics...
...Chiromics, while GSK could not be reached. Chiromics also could not be reached for details. Chiromics'...
BioCentury | Jan 16, 2012
Company News

Chiromics, Kadmon deal

...Kadmon received non-exclusive rights to use Chiromics' chemical compound libraries to discover and develop pharmaceutical products...
...indications. The libraries use organo-catalysis technology to produce drug-like molecules. Financial terms were not disclosed. Chiromics LLC...
Items per page:
1 - 4 of 4
BioCentury | Oct 6, 2014
Finance

Kadmon maneuvers

...and Co. (NYSE:LLY) for $6.8 billion in 2008. Kadmon has four drug discovery platforms: metabolomics; chiromics...
BioCentury | Nov 12, 2012
Company News

Chiromics, Bristol-Myers, GlaxoSmithKline deal

...pharmas to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics'...
...Bristol-Myers. Bristol-Myers and Chiromics did not disclose additional details, while GlaxoSmithKline could not be reached. Chiromics'...
...Chiromics was founded in 2009 by David MacMillan, a professor of chemistry at Princeton University. Chiromics LLC...
BioCentury | Nov 10, 2012
Company News

Chiromics in pair of pharma discovery deals

...NYSE:GSK) to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics'...
...and an exclusive license to a proprietary compound collection. Using its Chalis hit recognition algorithm, Chiromics...
...Chiromics, while GSK could not be reached. Chiromics also could not be reached for details. Chiromics'...
BioCentury | Jan 16, 2012
Company News

Chiromics, Kadmon deal

...Kadmon received non-exclusive rights to use Chiromics' chemical compound libraries to discover and develop pharmaceutical products...
...indications. The libraries use organo-catalysis technology to produce drug-like molecules. Financial terms were not disclosed. Chiromics LLC...
Items per page:
1 - 4 of 4